Endothelial expression of cell adhesion molecules (CAMs) plays an important role in atherosclerosis. Atherosclerosis is increased in hyperinsulinemic states, but whether insulin per se is proatherogenic remains unclear. To investigate the effects of hyperinsulinemia on CAM expression, plasma levels of ICAM-1, VCAM-1 and E-selectin were measured before and after forearm infusion of insulin in healthy subjects. Insulin administration for 2 h resulted in significant hyperinsulinemia, whereas no significant change was observed in soluble CAMs (all p > 0.05). Because insulin stimulates endothelial release of both endothelin-1 (ET-1) and nitric oxide (NO), which may modulate the expression of CAMs, we also investigated the response of CAMs to ET-1 receptor blockade, alone and in combination with NO synthesis inhibition. ET-1 receptor blockade during hyperinsulinemia resulted in a vasodilator response, but did not affect soluble CAMs (all p > 0.05). Superimposition of NO inhibition by L-NMMA reversed the vasodilator effect of ET-1 blockade, without affecting soluble CAMs (all p > 0.05). In conclusion, acute hyperinsulinemia, alone or during ET-1 and NO pathway blockade, does not affect soluble CAMs. These results do not support a direct effect of insulin on endothelial cells to affect leukocyte adhesiveness to the vascular wall.
Introduction
Expression of cell adhesion molecules (CAMs), such as intercellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1), and E-selectin on the surface of endothelial cells participates in various stages of the development and the progression of the atherosclerotic plaque by modulating the recruitment of leukocytes to lesion-prone sites of the arterial tree. 1, 2 As clearly shown by a number of studies over the last few years, hyperinsu-linemia=insulin resistance plays a central role in the pathophysiology of the metabolic syndrome, which, in turn, is associated with increased prevalence and severity of atherosclerosis. 3, 4 Several investigations have demonstrated an increased vascular expression of CAMs in these different conditions that are part of the metabolic syndrome, 5À8 even though the precise mechanisms underlying this phenomenon have not been fully elucidated. In particular, it is unclear whether hyperinsulinemia per se may directly activate vascular expression of CAMs, a question of relevance to ascertain the role of insulin as an independent risk factor for cardiovascular diseases.
Studies in our laboratory have previously shown that acute hyperinsulinemia results in the activation of both the endothelin (ET-1) system and the nitric oxide (NO) pathway within the vascular wall. 9 These results have recently been confirmed by studies performed in animals with selective knock-out of insulin receptors on endothelial cells, showing that disruption of these receptors is accompanied by suppression of both ET-1 and NO production. 10 Other studies have also shown that both ET-1 and NO importantly contribute to the regulation of CAMs expression on the surface of endothelial cells in response to inflammatory stimuli. Thus, increased ET-1 activity has been associated with enhanced endothelial expression of CAMs, 11, 12 a mechanism contributing to the proatherogenic action of ET-1. Conversely, NO is known to inhibit cytokine-induced CAM expression on endothelial cells by regulating the activation of nuclear factor kappa B (NF-jB), 13 a phenomenon likely involved in the antiatherogenic action of NO. Based on this evidence, therefore, it is possible to postulate that modulation of these vascular mediators may influence the expression of CAMs during hyperinsulinemia.
The present study was designed to investigate the effect of acute hyperinsulinemia on soluble CAMs. To this purpose, plasma levels of ICAM-1, VCAM-1 and Eselectin were measured before and after local infusion of insulin in a group of healthy subjects. We also investigated the response of soluble CAMs to ET-1 receptor blockade, alone and in combination with NO synthesis inhibition, during hyperinsulinemia.
Methods

Study population
Nine healthy volunteers with no family history of diabetes or hypertension were included after screening by clinical a National Heart, Lung, and Blood Institute, Bethesda, MD, USA; b Catholic University, Rome, Italy; c Gachon Medical Center, Inchon, South Korea; d Cardiovascular Research Institute, Washington, DC, USA history, physical examination, routine chemical analyses, electrocardiography, and chest radiography. This study was part of an investigation designed to assess the activity of the ET-1 system and the NO pathway in response to hyperinsulinemia. 9 Exclusion criteria were a history or evidence of present or past arterial hypertension, dyslipidemia, diabetes mellitus, obesity, cardiac disease, peripheral vascular disease, coagulopathy, or any other disease predisposing them to vasculitis or Raynaud's phenomenon. The study protocol was approved by the National Heart, Lung, and Blood Institute Investigational Review Board. Participants gave written informed consent for all procedures.
Study protocol
All studies were performed in the morning, after an overnight fast, in a quiet room with a temperature of approximately 22 C. Participants were asked to refrain from drinking alcohol or beverages containing caffeine and from smoking for at least 24 h before studies. While the participants were supine, a 20-gauge teflon catheter (Arrow, Inc.) was inserted into the brachial artery of the left arm for drug infusion and blood sampling. A 20-gauge catheter (Abbott Laboratories) was inserted in a deep antecubital vein of the same arm for blood sampling and another 20-gauge catheter was inserted in a deep antecubital vein of the contralateral arm for blood sampling and glucose infusion. Forearm blood flow was measured by venous occlusion strain-gauge plethysmography, blood pressure was recorded directly from the intraarterial catheter immediately after each flow measurement, and heart rate was continuously recorded by electrocardiogram. Volumes infused throughout the studies were matched by administration of saline in variable amounts.
On the study day, after the forearm was instrumented, subjects received intra-arterial infusion of saline for 15 min at 1 mL=min and baseline blood flow was measured. Then, subjects underwent intra-arterial infusion of regular insulin (Humulin; Eli Lilly) at 0.1 mU=kg of body weight per min (1 mL=min infusion rate) for 2 h. Throughout the study, in order to avoid any confounding effect related to changes in glycemia, plasma glucose levels were determined every 10 min during insulin administration and an infusion of 20% dextrose into the contralateral arm vein was adjusted to clamp glucose levels in the instrumented arm at values similar to baseline. The doses of glucose needed to clamp glycemic levels were generally very small in all subjects. Hemodynamic measurements were recorded every 30 min throughout the insulin infusion and blood samples for soluble CAMs were obtained after 2 h. This was followed by superimposing intra-arterial infusion of BQ-123 and BQ-788. BQ-123 (Bachem) is a synthetic peptide with high potency of antagonism for the ET A receptor. 14 BQ-788 (Peninsula) is a synthetic and highly selective antagonist of the ET B receptor. 15 BQ-123 (100 nmol=ml solution) was infused at 100 nmol=min (1 ml=min infusion rate) and BQ-788 (50 nmol=ml solution) was given at 50 nmol=min (1 ml=min infusion rate). BQ-123 and BQ-788 were infused for 2 h, forearm blood flow was measured every 10 min and plasma samples for soluble CAM measurement were obtained at the end of the 2-h period.
Then, intra-arterial infusion of L-NMMA (Calbiochem; 4 mmol=ml solution), an arginine analogue that competitively antagonizes the synthesis of NO from L-arginine, 16 was superimposed in each subject at 4 mmol=min (infusion rate of 1 ml=min). Blood flow measurements and plasma samples for soluble CAM assessment were again obtained after 30 min of L-NMMA infusion.
Analytical methods
All blood samples for laboratory assays were immediately centrifuged and stored at À70 C until analysis. ICAM-1, VCAM-1 and E-selectin were measured in triplicate in samples obtained from the infused forearm venous circulation by ELISA (R&D Systems). Plasma insulin levels were determined by RIA (Linco Research) and plasma glucose was measured by the glucose oxidase method.
Statistical analysis
Sample size was calculated a priori for the primary hypothesis that hyperinsulinemia would result in an increase in CAM plasma levels. These calculations showed that a sample size of nine subjects would allow detection, with a power of 80% at a ¼ 0.05, of a 20% increase in CAM circulating levels; such an increase may be considered of clinical relevance according to the results of some previous studies. 17, 18 In this study, one-way ANOVA was used to compare all treatment effects (saline, insulin, BQs and L-NMMA) on biochemical variables. One-way ANOVA for repeated measures was used to assess forearm blood flow changes from baseline. Treatment effects on forearm blood flow were analyzed by two-way ANOVA for repeated measures. All calculated p-values are twotailed, and a p-value less than 0.05 was considered to indicate statistical significance. All group data are reported as means AE SEM.
Results
Mean arterial pressure and heart rate did not change significantly after infusion of any of the substances used in this study, suggesting that the hemodynamic effects of the various drugs were limited to the infused forearm.
Insulin administration resulted in a marked increase in local insulin levels from the basal value of 3 AE 1 mU=ml. Thus, insulin concentrations in the infused forearm venous circulation were 269 AE 211 mU=ml after 2 h of insulin alone, 290 AE 204 mU=ml after ET-1 blockade, and 327 AE 208 mU=ml after L-NMMA ( p < 0.001 vs baseline), without significant difference among these three experimental conditions ( p > 0.05).
Forearm blood flow was similar at baseline (2.4 AE 0.7 ml=min=dl) and after 2 h of insulin administration (2.4 AE 0.7 ml=min=dl) ( p > 0.05). Similarly, plasma levels of ICAM-1, VCAM-1 and E-selectin were not significantly modified after 2 h of insulin infusion ( Figure  1) .
ET-1 receptor blockade during hyperinsulinemia resulted in a significant vasodilator response (from 2.5 AE 0.5 to 4.2 AE 1.7 ml=min=dl; p < 0.001), whereas it did not significantly affect circulating levels of ICAM-1, VCAM-1 and E-selectin (Figure 1 ). NO synthesis inhibition by L-NMMA during ET-1 receptor blockade in the presence of hyperinsulinemia was associated with a vasoconstriction that reversed the vasodilator effect of ET-1 blockade and allowed a return of forearm blood flow to values similar to those recorded at baseline (2.8 AE 0.7 ml=min=dl; p > 0.05 vs baseline). Circulating levels of ICAM-1, VCAM-1 and E-selectin, however, were not affected by NO synthesis inhibition (Figure 1 ).
Discussion
The main finding of the current study is that acute hyperinsulinemia does not modify plasma levels of ICAM-1, VCAM-1 and E-selectin in a group of healthy subjects. Our data are in keeping with those of other studies that have previously shown no direct effect of insulin infusion on soluble CAMs. Thus, De Mattia et al have reported that systemic administration of insulin during euglycemic clamp does not affect soluble VCAM-1 levels. 19 Similarly, Nagai et al have found that soluble adhesion molecule concentrations are not regulated by acute hyperinsulinemia in healthy men. 20 These results are apparently in contrast with those of other reports showing that soluble CAMs are increased in conditions of chronic hyperinsulinemia, as observed in those clinical states associated with insulin resistance. Thus, Ferri et al have found that elevations of plasma CAMs are evident in patients with multiple metabolic abnormalities. 21 Also, Matsumoto et al have reported high serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia. 22 One explanation for these discrepancies may be related to the possibility that, in insulin-resistant states, expression of CAMs is not dependent on a direct effect of insulin on endothelial cells, but rather on their stimulation by other factors, such as inflammatory molecules and other cytokines, which are known to be upregulated under those conditions. It is unlikely that the lack of effect of insulin infusion on soluble CAMs observed in our study may be attributable to inadequate insulin levels. Thus, the insulin doses given to our study participants resulted in local insulin concentrations in the high physiologic range. Similarly, we do not believe that the relatively short insulin infusion time importantly affected our study outcome, since even longer times of acute hyperinsulinemia have not resulted into substantial changes in plasma levels of soluble CAMs; 23 in contrast, other stimuli, such as endotoxemia, have been shown to induce considerable rises in plasma concentrations of CAMs even after shorter periods of infusion. 24 In our study, the blockade of ET-1 receptors during hyperinsulinemia, either alone or in combination with inhibition of NO biosynthesis, did not result in any significant change in soluble CAM concentrations, despite the significant hemodynamic effects associated with modulation of these vasoactive systems in the local circulation. The lack of effect of ET A=B receptor blockade on circulating CAM levels is apparently at odds with the results of previous studies, showing that higher plasma levels of ET-1 are associated with increased concentrations of soluble CAMs in patients with chronic heart failure. 25 Similarly, in contrast with our results, insulin has been previously shown to decrease the expression of ICAM-1 while concomitantly increasing the expression of eNOS in endothelial cells. Importantly, an insulin-induced decrease in ICAM-1 expression was prevented by the NOS inhibitor Insulin and cell adhesion molecules 187 N x -nitro-L-arginine, thus indicating that this phenomenon was related to increased availability of NO. 26 It must be noted, however, that other studies examining the effects of exogenous ET-1 infusion on circulating levels of CAMs have yielded results in line with those of the current study, by showing no significant modifications of these molecules after acute ET-1 administration. 27 It is worth noticing that, in the study of Jilma et al, 27 circulating levels of CAMs were unaffected by ET-1 infusion even after an observation period of 24 h, an adequate time to allow for transcriptional induction of all measured CAM RNA. This observation, therefore, further argues against the possibility that some action of the ET-1 system on CAM expression mediated by transcriptional mechanisms might have been undetected. Instead, and taken together with our current results, those findings strengthen the view that other factors, not operative in healthy volunteers under acute experimental conditions, are involved in the elevation of soluble CAMs observed in chronic disease states. We must also acknowledge that a change in soluble CAMs smaller than the threshold used for our sample size calculation might have been undetected as a consequence of a type II statistical error.
In conclusion, the results of the present study do not support the concept that a direct effect of insulin on endothelial cells is a mechanism affecting leukocyte adhesiveness to the vascular wall in healthy subjects. Further investigation is needed to clarify whether this mechanism is operative in those patients in whom increased levels of soluble CAMs may contribute to inflammation and atherosclerosis as well as to an increased prevalence of atherosclerosis-related cardiovascular events.
